Detalles de la búsqueda
1.
New synthetic molecules incorporated into polymeric micelles used for treatment against visceral leishmaniasis.
Cytokine;
177: 156543, 2024 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38373365
2.
Immunotherapy Combining Mimotopes Selected by Phage Display Plus Amphotericin B Is Effective for Treatment Against Visceral Leishmaniasis.
Parasite Immunol;
46(5): e13037, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38720446
3.
Treatment using vanillin-derived synthetic molecules incorporated into polymeric micelles is effective against infection caused by Leishmania amazonensis species.
Exp Parasitol;
260: 108743, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38513973
4.
Exploring drug repositioning for leishmaniasis treatment: Ivermectin plus polymeric micelles induce immunological response and protection against tegumentary leishmaniasis.
Cytokine;
164: 156143, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36774730
5.
In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasis.
Exp Parasitol;
251: 108555, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37247802
6.
Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis.
Parasitol Res;
122(12): 2917-2931, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37768367
7.
Recombinant guanosine-5'-triphosphate (GTP)-binding protein associated with Poloxamer 407-based polymeric micelles protects against Leishmania infantum infection.
Cytokine;
153: 155865, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35339043
8.
Sensitive and specific serodiagnosis of tegumentary leishmaniasis using a new chimeric protein based on specific B-cell epitopes of Leishmania antigenic proteins.
Microb Pathog;
162: 105341, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34883228
9.
Evaluation from a B-cell epitope-based chimeric protein for the serodiagnosis of tegumentary and visceral leishmaniasis.
Microb Pathog;
167: 105562, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35513293
10.
Leishmania LiHyC protein is immunogenic and induces protection against visceral leishmaniasis.
Parasite Immunol;
44(8): e12921, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35437797
11.
Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary study.
Exp Parasitol;
233: 108205, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34968460
12.
Leishmania eukaryotic elongation Factor-1 beta protein is immunogenic and induces parasitological protection in mice against Leishmania infantum infection.
Microb Pathog;
151: 104745, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33485994
13.
Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.
Med Microbiol Immunol;
210(2-3): 133-147, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33870453
14.
Diagnostic application of sensitive and specific phage-exposed epitopes for visceral leishmaniasis and human immunodeficiency virus coinfection.
Parasitology;
148(13): 1706-1714, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35060464
15.
Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
Exp Parasitol;
221: 108059, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33338468
16.
ChimLeish, a new recombinant chimeric protein evaluated as a diagnostic and prognostic marker for visceral leishmaniasis and human immunodeficiency virus coinfection.
Parasitol Res;
120(12): 4037-4047, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34664113
17.
Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis.
Parasitol Res;
120(1): 321-335, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33191446
18.
A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
Cell Immunol;
356: 104194, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32827943
19.
Biotechnological applications from a Leishmania amastigote-specific hypothetical protein in the canine and human visceral leishmaniasis.
Microb Pathog;
147: 104283, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32485231
20.
An immunoproteomics approach to identify Leishmania infantum proteins to be applied for the diagnosis of visceral leishmaniasis and human immunodeficiency virus co-infection.
Parasitology;
147(9): 932-939, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32308186